Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) | Société Générale S.A. |
| Company dealt in | UDG Healthcare plc |
| Class of relevant security to which the dealings being disclosed relate (Note 2) | €0.05 ordinary shares |
| Date of dealing | 23/07/2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
|
| Long | Short | ||
| Number | (%) | Number | (%) | |
| (1) Relevant securities | 17,014,787 | 6.75 | 13,262 | 0.01 |
| (2) Derivatives (other than options) | 0 | 0.00 | 11,218,405 | 4.45 |
| (3) Options and agreements to purchase/sell | 0 | 0.00 | 0 | 0.00 |
| Total | *17,319,171 | *6.87 | 11,231,667 | 4.46 |
* Include the holding of 304,384 shares on borrow products
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
| Class of relevant security: | Long | Short | ||
|
| Number | (%) | Number | (%) |
| (1) Relevant securities |
|
|
|
|
| (2) Derivatives (other than options) |
|
|
|
|
| (3) Options and agreements to purchase/sell |
|
|
|
|
| Total |
|
|
|
|
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
| Purchase/sale | Number of relevant securities | Price per unit GBP (Note 5) |
| Purchase | 68 | 10.78 |
| Purchase | 188 | 10.78 |
| Purchase | 1 | 10.78 |
| Purchase | 207 | 10.78 |
| Purchase | 102 | 10.78 |
| Purchase | 102 | 10.78 |
| Purchase | 962 | 10.78 |
| Purchase | 482 | 10.78 |
| Purchase | 372 | 10.78 |
| Purchase | 300 | 10.78 |
| Purchase | 928 | 10.78 |
| Purchase | 285 | 10.78 |
| Purchase | 214 | 10.78 |
| Purchase | 282 | 10.78 |
| Purchase | 181 | 10.78 |
| Purchase | 1,859 | 10.78 |
| Purchase | 138 | 10.78 |
| Sale | 1,061 | 10.79 |
| Sale | 884,981 | 10.75 |
| Sale | 76,858 | 10.79 |
| Total Purchases | 6,671 |
|
| Total Sales | 962,900 |
|
Derivatives transactions (other than options transactions)
| Product name, | Nature of transaction | Number of relevant securities | Price per unit GBP |
|
|
|
|
|
(b) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
| Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
|
(ii) Exercising
| Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
|
(c) Other dealings (including transactions in respect of new securities) (Note 4)
| Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements, or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other
person relating to the voting rights of any relevant securities under any option referred to on this form or relating
to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred
to on this form is referenced. If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9) No
| Date of disclosure | 26/07/2021 |
| Contact name | Société Générale - Disclosure team |
| Telephone number | +33 1 42 14 92 74 |
| If a connected EFM, name of offeree/offeror with which connected |
|
| If a connected EFM, state nature of connection (Note 10) |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
